AddLife (BATS-CHIXE:ALIFBS) - Aktienkurs, Nachrichten und Analyse

ALIFBS Aktienübersicht

Provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.

Über das Unternehmen

ALIFBS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	4/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 22% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Gewinnspannen (3.1%) sind niedriger als im Vorjahr (6.7%)

AddLife AB (publ) Wettbewerber

Ergomed

AIM:ERGO

UK£701.1m

hVIVO

AIM:HVO

UK£183.4m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für AddLife
Historische Aktienkurse
Aktueller Aktienkurs	SEK 65.25
52-Wochen-Hoch	SEK 140.00
52-Wochen-Tief	SEK 65.25
Beta	1.19
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	-39.67%
33 Jahre Veränderung	-54.62%
5 Jahre Veränderung	15.74%
Veränderung seit IPO	67.85%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	ALIFBS	GB Life Sciences	GB Markt
7D	0%	0.9%	-1.0%
1Y	-39.7%	-40.5%	7.3%

Rendite im Vergleich zur Industrie: ALIFBS unter dem Niveau der Branche UK Life Sciences, die im vergangenen Jahr eine Rendite von -42.9% erzielte.

Rendite vs. Markt: ALIFBS hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 7 erzielte.

Preisvolatilität

Is ALIFBS's price volatile compared to industry and market?
ALIFBS volatility
ALIFBS Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stabiler Aktienkurs: ALIFBS hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von ALIFBS im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1906	2,314	Fredrik Dalborg	www.add.life

AddLife AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von AddLife im Vergleich zum Marktanteil des Unternehmens?
ALIFBS grundlegende Statistiken
Marktanteil	SEK 13.33b
Gewinn(TTM)	SEK 292.00m
Umsatz(TTM)	SEK 9.47b

45.7x

Kurs-Gewinn-Verhältnis

1.4x

Kurs-Umsatz-Verhältnis

Ist ALIFBS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ALIFBS Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 9.47b
Kosten der Einnahmen	SEK 5.92b
Bruttogewinn	SEK 3.54b
Sonstige Ausgaben	SEK 3.25b
Umsatz	SEK 292.00m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

Feb 02, 2024

Gewinn per Aktie (EPS)	2.40
Bruttomarge	37.44%
Nettogewinnspanne	3.08%
Schulden/Eigenkapital-Verhältnis	102.1%

Wie hat sich ALIFBS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.1%

Aktuelle Dividendenrendite

50%

Ausschüttungsquote

ALIFBS Aktienübersicht

Belohnungen

Risikoanalyse

AddLife AB (publ) Wettbewerber

AIM:ERGO

UK£701.1m

AIM:HVO

UK£183.4m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

AddLife AB (publ) to Report Q1, 2025 Results on Apr 25, 2025

AddLife AB (publ) Approves Dividend, Payable on 16 May 2024

AddLife AB (publ) to Report Fiscal Year 2024 Results on Feb 05, 2025

AddLife AB (publ) to Report Fiscal Year 2023 Results on Apr 05, 2024

AddLife AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

AddLife AB (publ) to Report First Half, 2024 Results on Jul 15, 2024

Recent updates

AddLife AB (publ) to Report Q1, 2025 Results on Apr 25, 2025

AddLife AB (publ) Approves Dividend, Payable on 16 May 2024

AddLife AB (publ) to Report Fiscal Year 2024 Results on Feb 05, 2025

AddLife AB (publ) to Report Fiscal Year 2023 Results on Apr 05, 2024

AddLife AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

AddLife AB (publ) to Report First Half, 2024 Results on Jul 15, 2024

AddLife AB (publ), Annual General Meeting, May 08, 2024

Second quarter 2023 earnings released: EPS: kr0.27 (vs kr0.61 in 2Q 2022)

Independent Director recently bought kr12m worth of stock

Investor sentiment improves as stock rises 37%

President & CEO recently bought kr129k worth of stock

Addlife AB (Publ) Declares Dividend

Upcoming dividend of kr1.20 per share at 1.0% yield

President & CEO recently bought kr139k worth of stock

President & CEO recently bought kr112k worth of stock

AddLife AB (publ) Proposes Dividend for the Year Ended December 31, 2022

President & CEO recently bought kr285k worth of stock

Håkan Roos acquired a 0.246285% stake in AddLife AB (publ) for SEK 30 million.

AddLife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

AddLife AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

Second quarter 2022 earnings released

Now 23% undervalued after recent price drop

Investor sentiment deteriorated over the past week

CFO & Business Area Manager of Medtech recently sold kr8.5m worth of stock

Addlife AB (Publ) Approves Dividend, Payable on 12 May 2022

AddLife AB (publ) Appoints Fredrik Dalborg as President

Full year 2021 earnings released: EPS: kr6.02 (vs kr4.62 in FY 2020)

AddLife AB (publ) (OM: ALIF B) acquired O'Flynn Medical Limited.

Addlife AB (Publ) Proposes Dividend, Payable on 12 May 2022

Investor sentiment improved over the past week

AddLife AB (publ) (OM:ALIF B) completed the acqusitions of Telia Health Monitoring.

President & CEO recently bought kr5.8m worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Addlife AB (Publ) Proposes Dividend

Addlife AB (Publ) Announces Step Down of Kristina Willgård as Chief Executive Officer

AddLife AB (publ) (OM:ALIF B) completed the acquisition of MBA Incorporado S.A from Alantra Private Equity.

Investor sentiment deteriorated over the past week

AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire MBA Incorporado S.A from Alantra Private Equity for approximately €110 million.

AddLife AB (publ) (OM:ALIF B) signed an agreement to acquire Telia Health Monitoring.

Beijing AddLife AB (publ) (OM:ALIF B) acquired Camanio AB from Brighter AB (publ) (OM:BRIG) for SEK 65 million.

President & CEO recently sold kr32m worth of stock

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Independent Chairman recently sold kr11m worth of stock

AddLife AB (publ) (OM:ALIF B) acquired Bio-Connect BV.

Investor sentiment improved over the past week

Chief Financial Officer recently sold kr106k worth of stock

Independent Chairman recently sold kr7.0m worth of stock

Second quarter 2021 earnings released: EPS kr1.46 (vs kr1.07 in 2Q 2020)

Investor sentiment improved over the past week

Chief Financial Officer recently sold kr14m worth of stock

Independent Director has left the company

AddLife AB (publ) Approves Dividend, Payable on 12 May 2021

First quarter 2021 earnings released

Upcoming dividend of kr1.50 per share

AddLife AB (Publ) Provides Earnings Guidance for 2021

New 90-day high: kr175

Full year 2020 earnings released: EPS kr4.62 (vs kr1.27 in FY 2019)

New 90-day high: kr169

Erträge & Einnahmen